Cargando…
Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study
BACKGROUND: We have previously demonstrated that high tumor tissue levels of TIMP-1 are associated with no or limited clinical benefit from chemotherapy with CMF and anthracyclines in metastatic breast cancer patients. Here, we extend our investigations to the adjuvant setting studying outcome after...
Autores principales: | Schrohl, Anne-Sofie, Look, Maxime P, Meijer-van Gelder, Marion E, Foekens, John A, Brünner, Nils |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754488/ https://www.ncbi.nlm.nih.gov/pubmed/19744322 http://dx.doi.org/10.1186/1471-2407-9-322 |
Ejemplares similares
-
Differential effects of tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 on atherosclerosis and monocyte/macrophage invasion
por: Di Gregoli, Karina, et al.
Publicado: (2016) -
Role of tissue inhibitors of metalloproteinases (TIMPs) in colorectal carcinoma.
por: Joo, Y. E., et al.
Publicado: (1999) -
Expression of Tissue Inhibitors of Metalloproteinases (TIMPs) in Hepatocellular Carcinoma
por: Joo, Young-Eun, et al.
Publicado: (2000) -
An evaluation of matrix metalloproteinase-9 (Mmp-9) and tissue inhibitor metalloproteinase-1 (Timp-1) Serum levels and the Mmp-9/Timp-1 Ratio in Covid-19 patients
por: Demir, Nazlim Aktug, et al.
Publicado: (2023) -
Tissue Inhibitor of Matrix Metalloproteinases-1 (TIMP-1) and Pulmonary Involvement in COVID-19 Pneumonia
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2023)